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ABSTRACT
Background: ()-Hydroxycitrate (HCA), a competitive inhibitor
of ATP-citrate lyase, should reduce the extramitochondrial
acetyl-CoA pool. It has been hypothesized that HCA ingestion
can reduce malonyl-CoA concentrations and consequently
increase fatty acid oxidation in vivo.
Objective: This study investigated the acute effects of HCA sup-
plementation on substrate utilization at rest and during exercise
in endurance-trained humans.
Design: Ten cyclists [(x– ± SD) age: 24 ± 2 y, weight: 73 ± 2 kg,
maximal oxygen uptake: 4.95 ± 0.11 L/min, maximal work out-
put (Wmax): 408 ± 8 W] were studied at rest and during 2 h of
exercise at 50% Wmax on 2 occasions. Both 45 and 15 min
before exercise and 30 and 60 min after the start of exercise,
3.1 mL/kg body wt of an HCA solution (19 g/L) or placebo was
ingested. Total fat and carbohydrate oxidation rates were
assessed. Blood samples were collected at 15-min intervals at
rest and every 30 min during exercise.
Results: Plasma HCA concentrations increased after HCA
ingestion up to 0.39 ± 0.02 mmol/L (82.0 ± 4.8 mg/L). However,
no significant differences in total fat and carbohydrate oxidation
rates were observed between trials. Accordingly, plasma glucose,
glycerol, and fatty acid concentrations did not differ between tri-
als. Plasma lactate concentrations were significantly lower in the
HCA than in the placebo trial after 30 min of exercise but at the
end of the exercise period they did not differ between trials.
Conclusion: HCA, even when provided in large quantities, does
not increase total fat oxidation in vivo in endurance-trained
humans. Am J Clin Nutr 2000;72:1445–50.
KEY WORDS ()-Hydroxycitrate, HCA, Garcinia cambogia,
fat oxidation, obesity, dietary supplement, weight loss
INTRODUCTION
Recently, a lot of publicity has been generated concerning
a compound known as ()-hydroxycitrate (HCA). HCA is
being promoted as the new natural aid to losing weight and
many promises about its effect on metabolism and appetite are
being made.
HCA is a principal constituent in the rind of the fruit of Garcinia
cambogia, which is used in the preparation of curries and condi-
ments in Asian cuisine. HCA appears to be well tolerated and has
a chemical structure much like that of citric acid. Consequently,
HCA is now added extensively to a wide variety of nutritional sup-
plements. Although the toxicologic safety of HCA is often stated,
we are not familiar with published studies that actually investigated
the safety (short- or long-term) of HCA supplementation. The
knowledge that HCA could have an important effect on metabolism
is not new—Sullivan and coworkers were already doing research
on HCA in the 1970s (1–8). Although the clinical relevance of
HCA as an effective antiobesity agent has often been proposed
(1, 9–12), very little research has been performed to investigate the
metabolic effects of HCA supplementation in vivo in humans.
HCA is a competitive inhibitor of ATP-citrate lyase (EC
4.1.3.8), the enzyme catalyzing the extramitochondrial cleavage
of citrate to oxaloacetate and acetyl-CoA (5, 8, 13, 14). The
action of HCA should reduce the acetyl-CoA pool, thus limiting
the availability of 2-carbon units required for fatty acid and cho-
lesterol biosynthesis. This has led to suggestions that HCA
administration could inhibit lipogenesis. This was confirmed by
several studies in which HCA administration (predominantly in
rodents) inhibited the in vivo and in vitro rates of lipogenesis in
several tissues known to convert carbohydrate into fatty acids,
namely liver, adipose tissue, and small intestine (2, 4, 6–8,
15–17). HCA administration could also have an effect on fatty
acid oxidation itself. Because extramitochondrial cleavage of cit-
rate is the penultimate step in the conversion of glucose to mal-
onyl-CoA, suggestions have been made that administration of
HCA, by reducing the acetyl-CoA concentration, could reduce
cytosolic malonyl-CoA concentrations and increase fatty acid
oxidation (18–21). In support of this hypothesis, Chen et al (22)
observed an increase in [1–1-4C]palmitate oxidation rate in iso-
lated islets from rat pancreas when perfused with HCA.
The implication of the latter mechanisms, when operative in
vivo, is that HCA could be useful as a metabolic antiobesity agent.
In addition, HCA supplementation has also been suggested as an
ergogenic aid, especially because an increase in fat oxidative
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capacity would limit endogenous carbohydrate utilization during
aerobic exercise (20, 21). Suggestions have also been made that
increases in malonyl-CoA lead to insulin resistance in diabetic
mice models (23). As such, a nutritional compound that could
lower muscle malonyl-CoA concentration and increase fat oxida-
tion would be extremely important. To date, only one recent study
has investigated the effects of a small dose of HCA on total fat oxi-
dation in humans (24). However, there are no data available that
provide information about intestinal absorption and plasma avail-
ability after HCA supplementation. Therefore, no conclusions on
the potential of HCA to increase muscle fat oxidation can be made.
This study investigated the acute effects of ingestion of HCA
(6–30 times the reported dosage applied in human weight-loss
studies) on plasma HCA availability. We further investigated
whether systemic HCA availability altered fat oxidation rates
and plasma metabolite concentrations at rest and during moder-
ate-intensity exercise in endurance-trained humans.
SUBJECTS AND METHODS
Subjects
Ten cyclists [(x– ± SD) age: 24.4 ± 1.6 y, height: 1.82 ± 0.02 m,
weight: 73.2 ± 1.8 kg, body mass index (BMI; in kg/m2):
22.1 ± 0.5, maximal oxygen uptake ( ·VO2max): 4.95 ± 0.1 L/min,
maximal work output (Wmax): 408 ± 8 W] participated in the
study. All subjects were informed about the nature and putative
risks of the experimental procedures before their informed con-
sent was obtained. This study was approved by the local Ethical
Committee of the Academic Hospital Maastricht.
Pretesting
·VO2max and Wmax were measured on an electronically braked
cycle ergometer (Lode, Groningen, Netherlands) during an
incremental exhaustive exercise test 1 wk before the first exper-
imental trial (25). These findings were used to determine the
50% Wmax workload that was used in the following trials.
Experimental trials
In a pilot study, we determined plasma HCA concentrations
after the ingestion of a single bolus of HCA solution (4.4 g) over
a 3.5-h period in 3 male subjects who were not included in the
main study. All subjects performed 2 experimental trials consist-
ing of 1 h of supine rest and 2 h of moderate-intensity cycling
exercise at 50% Wmax (55% ·VO2max). During each trial, sub-
jects ingested a total beverage volume of 12.5 mL/kg body wt.
Beverages contained water or water with added HCA. Beverages
were provided in randomized order and double blind. All drinks
were flavored to camouflage the taste in both trials. Subjects
were instructed to refrain from heavy physical labor and
recorded their food intake for 2 d before the first trial; these
records were used to standardize diet before the second trial. In
addition, the evening before each trial, subjects received under
supervision a standardized high-carbohydrate meal (85 kJ/kg
body wt) that provided 69% of energy as carbohydrate, 15% as
fat, and 16% as protein in the laboratory. Thereafter, subjects
abstained from food intake and exercise until the trials.
Protocol
Subjects reported to the laboratory at 0800 after an overnight
fast. A Teflon catheter (Baxter, Utrecht, Netherlands) was
inserted into an antecubital vein. Gas exchange measurements
were performed continuously over a 30-min resting period by
using a ventilated-hood system (Oxycon ; Mijnhardt, Mannheim,
Germany). Thereafter, a blood sample was taken and subjects
received the first bolus of test drink (t = 45), after which gas
exchange measurements were continued for another 30 min.
Blood samples were taken at 15-min intervals until t = 0. Sub-
jects received a second bolus 15 min before exercise (t = 15).
After a warming-up period of 5 min at 100 W, subjects started
cycling at a moderate intensity of 50% Wmax for 2 h (t = 0–120).
During exercise, subjects received another bolus of test drink at
t = 30 and at t = 60. During exercise, blood samples were taken
at 30-min intervals (t = 30 and 60) and breath gases were ana-
lyzed every 10 min before a blood sample was taken.
Beverages
All subjects received a total of 0.5 g/kg body wt of a liquid
G. cambogia extract [Citrimax HCA-450-LS (48% HCA); Inter-
health Nutritionals, Benicia, CA] by ingesting 12.5 mL/kg body
wt of a 4% solution (38 g/L), which was divided over 4 boluses.
This resulted in 18 ± 0.4 g HCA being ingested by every subject
in the HCA trial. To diminish the acidity of the solution, 0.1 mol
NaOH/L was added for each 1 L of HCA drink. The placebo
drink was flavored by adding 20 mg quinine sulfate/L. To
improve palatability, both drinks were artificially sweetened by
adding 10 mL liquid artificial sweetener containing both cycla-
mate and saccharine (Natrena BV, Utrecht, Netherlands) for each
1 L of placebo or HCA drink. Beverages were provided in a ran-
domized order and double blind.
Analysis
Blood (7 mL) was collected in EDTA-containing tubes and
centrifuged at 1000  g and 4 C for 5 min. Aliquots of plasma
were frozen immediately in liquid nitrogen and stored at 40 C.
Plasma glucose (Uni Kit III, 07367204; Roche, Basel, Switzer-
land), lactate (26), fatty acid (Wako NEFA-C kit; Wako Chemi-
cals, Neuss, Germany), and glycerol (UV method, 148270;
Boehringer Mannheim GmbH, Mannheim, Germany) concentra-
tions were analyzed with the Cobas Fara semiautomatic analyzer
(Roche). Plasma HCA analysis was set up by the TNO Institute,
using a Dionex DX500 chromatography system equipped with
an IonPac AS 11 column (4.6  250 mm; Dionex, Sunnyvale,
CA) at a flow rate of 0.002 L/min. HCA was analyzed with a
concentration gradient of NaOH starting with 0.5 mmol NaOH/L
for 2.5 min, followed by subsequent linear concentration gradi-
ents of 0.5–5 mmol NaOH/L in 3.5 min, and 5–38.25 mmol/L
NaOH in 12 min. Detection was performed by suppressed con-
ductivity. The same analytic procedure was used to determine the
contents of the applied G. cambogia extract (Citrimax HCA-450-
LS). The water content of this liquid extract was 35% by weight.
HCA content was 0.48 g/g extract (48%). The extract further
contained small amounts of other organic acids (phosphoric acid
and citric acid: 1.7% and 0.9%, respectively), fluoride (0.2%),
chloride (2.0%), and sulfate (1.9%). The contents of caffeine and
related compounds (theobromine and theophylline) were below
the detection threshold (< 25 g/g extract).
Calculations
From the recorded maximal carbon dioxide output ( ·VCO2) and
·VO2 (Oxycon-), total carbohydrate and total fat oxidation rates
and energy expenditure were calculated (27) as follows:
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Carbohydrate oxidation = 4.585 ·VCO2 – 3.226
·VO2 (1)
Fat oxidation = 1.695 ·VO2 – 1.701
·VCO2 (2)
Statistics
All data are expressed as means ± SEMs. Paired t tests were
applied to compare differences in substrate utilization between
the placebo and HCA trial. Analysis of variance for repeated
measures (with interaction) was performed to study differences
over time between trials. A post hoc Scheffe’s test was applied in
case of a significant F ratio to locate the differences between tri-
als. Statistical significance was set at P < 0.05.
RESULTS
In the pilot study, plasma HCA concentrations increased over
time after ingestion of a single dose of HCA (4.4 g). Maximal
values were attained after 60–90 min (0.12 ± 0.03 mmol/L), after
which concentrations decreased (Figure 1).
In the main study, plasma HCA concentrations increased up
to 0.08 ± 0.01 mmol/L (16.6 mg/L) after the ingestion of
4.4 ± 0.1 g HCA at t = 45 and t = 15 during resting condi-
tions (Figure 1). No HCA was detected in the plasma samples
collected in the placebo trial (Figure 1). Respiratory measure-
ments ( ·VO2 and ·VCO2) and respiratory exchange ratios (RERs)
are illustrated in Figure 2 and Figure 3, respectively. During
resting conditions, ·VO2,
·VCO2, and RER were not significantly
different between trials and did not change significantly after
the ingestion of the first bolus of the HCA or control drink. The
relative contribution of fat and carbohydrate oxidation to total
energy expenditure is shown in Figure 4. Energy expenditure at
rest after ingestion of the first bolus of test drink (at t = 15)
averaged 5.7 ± 0.6 and 5.7 ± 0.6 kJ/min in the control and HCA
trial, respectively. Fat oxidation rates were similar in both trials
and averaged 0.07 ± 0.02 and 0.07 ± 0.02 g/min, respectively.
Plasma fatty acid, glycerol, glucose, or lactate concentrations
are shown in Figure 5. No significant differences in plasma
fatty acids, glycerol, glucose, and lactate concentrations were
observed between the trials at rest.
Plasma HCA concentrations increased further up to
0.39 ± 0.02 mmol/L (82.0 ± 4.8 mg/L) after the ingestion of
4.4 ± 0.1 g HCA after 30 and 60 min of exercise in the HCA trial
(Figure 1). ·VO2 and ·VCO2 increased from rest to exercise (Figure
2). RERs tended to decrease over time and averaged 0.857 ± 0.02
and 0.859 ± 0.02 during the second hour of exercise in the control
and HCA trial, respectively (Figure 3). Energy expenditure during
this period averaged 60.2 ± 5.5 kJ/min in the control and 59.6 ± 5.4
kJ/min in the HCA groups. Fat oxidation was similar in both trials
(0.68 ± 0.1 and 0.66 ± 0.1 g/min, respectively) (Figure 4). During
exercise, fatty acid and glycerol concentrations increased over time
and plasma glucose values tended to decrease (Figure 5). No signi-
ficant differences between trials were observed for plasma fatty
acid, glycerol, and glucose concentrations. Plasma lactate concen-
trations showed an inital increase during the first 30 min of exer-
cise, after which concentrations stabilized. Significantly lower
plasma lactate concentrations were observed in the HCA trial after
30 min of exercise. Throughout the remaining exercise period, lac-
tate concentrations tended to be lower in the HCA trial. However,
after 120 min of exercise, plasma lactate concentrations were sim-
ilar in both trials (Figure 5).
DISCUSSION
In a pilot study, we determined plasma HCA concentrations
after the ingestion of 4.4 ± 0.2 g HCA, which is a relatively large
amount compared with the small doses applied in previous sup-
plementation studies in humans (24, 28) and advised in commer-
cial weight-loss regimens. To date, only 2 studies (24, 28) have
investigated the effects of HCA ingestion in humans, and plasma
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FIGURE 1. Mean (± SEM) plasma ()-hydroxycitrate (HCA) con-
centrations in the pilot study after the ingestion of a single dose of HCA
(n = 3) and in the HCA and placebo trials (n = 10).
FIGURE 2. Mean (± SEM) oxygen uptake ( ·VO2) and carbon dioxide
production ( ·VCO2). There were no significant differences between trials.
n = 10. HCA, ()-hydroxycitrate.
HCA concentrations have never been assessed. Therefore, the
bioavailability of HCA supplements was the subject of intense
debate (9, 11, 12) after the publication of the study by Heyms-
field et al (28). The results of our pilot study show that the
ingested HCA is absorbed in the gastrointestinal tract and enters
the systemic circulation, which is of primary importance if HCA
is to reach the target cells and induce its suggested effect on
skeletal muscle fuel selection.
To investigate the ability of HCA supplementation to increase
skeletal muscle fat oxidation, we provided subjects with a large
amount of HCA (a total of 18 ± 0.4 g HCA divided over 4 doses
of 4.4 ± 0.1 g) to increase and maintain high plasma HCA con-
centrations during exercise. Ingestion of the HCA solution
resulted in an increase in plasma HCA concentration up to
0.08 ± 0.01 mmol/L during rest, and continued ingestion further
increased plasma HCA concentration up to 0.39 ± 0.02 mmol/L
during exercise (Figure 1). The amount of HCA ingested
(18 ± 0.4 g) in the present study is 6–30 times higher than the
doses applied in other studies (24, 28) and prescribed by food
supplement producers, which are not based on any scientific lit-
erature. In the present study, we applied such a relatively large
dose to provide subjects with 10–20% of the amount of HCA
that had been administered in the rodent studies.
Although we showed that ingestion of large amounts of HCA
results in a substantial increase in plasma HCA concentration,
we observed no significant differences in ·VO2 and
·VCO2 at rest
or during exercise between the placebo and HCA trial (Figure 2).
The gradual increase in fat oxidation during exercise, as indi-
cated by the decrease in RER (Figure 3), was also similar in both
trials. Consequently, energy expenditure and fat and carbohy-
drate oxidation at rest and during exercise were not significantly
different between trials (Figure 4). In addition, we did not
observe any significant differences in plasma fatty acid, glycerol,
or glucose concentrations between trials. We conclude that
plasma HCA availability does not increase energy expenditure or
stimulate skeletal muscle fat oxidation at rest or during exercise
in vivo in endurance-trained humans. It is possible that the
absence of an effect on fat oxidation could be explained by the
already increased oxidative capacity in the endurance-trained
state. However, even in these trained subjects, fat oxidation rates
were shown to increase during the 2 h of exercise and, although
this is proposed to be caused directly by an exercise-induced
decrease in muscle malonyl-CoA concentration (29), plasma
HCA availability did not affect these changes in fat oxidation.
During exercise, lactate concentrations tended to be lower in
the HCA trial than in the placebo trial during the first 90 min of
exercise. The difference was significant only at 30 min (Figure 5).
These initial differences could be explained by the fact that HCA
has been shown to promote gluconeogenesis in rodent liver (3–8,
30). Potentially, HCA supplementation in the present study
increased the rate of lactate conversion to glucose in the liver with
a subsequent reduction in plasma lactate concentration. These
findings may imply that HCA supplementation affects metabo-
lism in hepatic tissue in humans rather than in skeletal muscle.
HCA administration was shown to significantly inhibit the in
vivo and in vitro rates of lipogenesis in rodent liver, adipose tis-
sue, and small intestine (2, 4, 6–8, 15–17), but this has not been
confirmed in human tissues. However, de novo lipogenesis is
normally regarded as being of little importance in the develop-
ment of obesity (31, 32). Therefore, in order for HCA to qualify
as an effective metabolic antiobesity agent, it should produce a
stimulating effect on skeletal muscle fat oxidation or total
energy expenditure. In the present study, we showed that HCA
supplementation is ineffective in increasing fat oxidation in
endurance-trained subjects, even in the large doses. Although in
this study only endurance-trained, nonobese subjects were
selected, we did not detect any indication that HCA supplemen-
tation can affect whole-body metabolism in humans. As such,
the only applicability of HCA as an antiobesity agent seems to
be the suggested reduction of appetite and food intake (7, 19,
33). However, the pathways by which HCA supplementation
could reduce dietary intake remain unclear and there are no data
available in the literature that provide any direct evidence for an
appetite-suppressing effect and reduced dietary intake after
HCA supplementation. These matters remain to be investigated
and should include measurement of plasma HCA concentrations
to determine whether and to what extent a certain dose of HCA
can inhibit dietary intake and be an effective aid in weight-loss
studies in humans (9, 11, 12, 28).
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FIGURE 4. Mean (± SEM) energy expenditure at rest and during
exercise in the ()-hydroxycitrate (HCA) and placebo trials. There were
no significant differences between trials. n = 10.
FIGURE 3. Mean (± SEM) respiratory exchange ratios. There were
no significant differences between trials. n = 10.
In conclusion, this study showed that large doses of G. cam-
bogia extract do get absorbed in the intestine and can lead to a
substantial increase in plasma HCA concentrations. However,
this does not affect fat and carbohydrate oxidation rates at rest or
during moderate-intensity exercise in endurance-trained humans.
Accordingly, a direct effect of HCA on fat oxidation seems
unlikely to contribute to its claimed antiobesity or ergogenic
potential.
We gratefully acknowledge the support of Barbara Veldhuis, who per-
formed the plasma HCA measurements.
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